Related Experiment Videos
Childhood immunization guidelines: current and future
1Department of Family Medicine and Clinical Epidemiology, University of Pittsburgh School of Medicine, PA 15261.
Insights
New vaccines and updated immunization schedules are available for infants and adolescents. Key vaccines include acellular pertussis, hepatitis B, and Haemophilus influenzae type b, with specific recommendations for influenza and pneumococcal vaccines for high-risk children.
Area of Science:
- Pediatrics
- Immunology
- Public Health
Background:
- The immunization schedule is continuously updated to incorporate new vaccines and recommendations.
- Recent advancements include acellular pertussis and hepatitis B vaccines for infants and adolescents.
Purpose of the Study:
- To inform healthcare providers and the public about recent changes and additions to the childhood immunization schedule.
- To highlight specific vaccine recommendations for different age groups and risk factors.
Main Methods:
- Review of current immunization guidelines and newly licensed vaccines.
- Summarization of recommended vaccination timings and target populations.
Main Results:
- Acellular pertussis and hepatitis B vaccines are now part of routine infant immunization.
- Oral poliovirus vaccine (OPV) third dose recommended at 6 months; MMR vaccine first dose at 12-15 months.
- A new vaccine for Haemophilus influenzae type b is available. Influenza vaccine recommended for children 6 months+ with chronic conditions; pneumococcal vaccine for children 2 years+ with specific conditions like asplenia or immunosuppression.
Conclusions:
- Updated immunization schedules aim to improve protection against vaccine-preventable diseases.
- Targeted vaccination strategies are recommended for high-risk pediatric populations.
- Adherence to recommended schedules and consideration of new vaccines are crucial for child health.
Abstract:
Recent additions to the immunization schedule include acellular pertussis vaccine, and hepatitis B vaccine for all infants and selected adolescents. The third dose of OPV is recommended at 6 months of age and the first dose of MMR vaccine at 12 to 15 months. A new vaccine against Haemophilus influenzae type b has been licensed. Children aged 6 months and older with asthma, diabetes, or heart disease should receive influenza vaccine. Children aged 2 years and older with asplenia, immunosuppression, and nephrotic syndrome may be candidates for pneumococcal immunization.